Pacira BioSciences, Inc. (PCRX)
USD 26.45
(-1.12%)
USD 26.45
(-1.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 674.97 Million USD | 1.22% |
| 2022 | 666.82 Million USD | 23.14% |
| 2021 | 541.53 Million USD | 28.68% |
| 2020 | 420.83 Million USD | -0.05% |
| 2019 | 421.02 Million USD | 24.83% |
| 2018 | 337.27 Million USD | 17.67% |
| 2017 | 286.63 Million USD | 3.71% |
| 2016 | 276.37 Million USD | 10.99% |
| 2015 | 248.99 Million USD | 25.97% |
| 2014 | 197.66 Million USD | 131.05% |
| 2013 | 85.55 Million USD | 118.89% |
| 2012 | 39.08 Million USD | 149.12% |
| 2011 | 15.68 Million USD | 7.74% |
| 2010 | 14.56 Million USD | -2.96% |
| 2009 | 15 Million USD | 7.76% |
| 2008 | 13.92 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 178.02 Million USD | 6.53% |
| 2024 Q1 | 167.11 Million USD | -7.79% |
| 2023 Q3 | 163.92 Million USD | -3.27% |
| 2023 Q4 | 181.24 Million USD | 10.56% |
| 2023 FY | 674.97 Million USD | 1.22% |
| 2023 Q2 | 169.46 Million USD | 5.69% |
| 2023 Q1 | 160.34 Million USD | -6.75% |
| 2022 Q4 | 171.95 Million USD | 2.68% |
| 2022 Q2 | 169.41 Million USD | 7.23% |
| 2022 Q1 | 157.99 Million USD | -0.76% |
| 2022 FY | 666.82 Million USD | 23.14% |
| 2022 Q3 | 167.46 Million USD | -1.15% |
| 2021 Q2 | 135.59 Million USD | 13.92% |
| 2021 Q1 | 119.02 Million USD | -7.41% |
| 2021 Q4 | 159.19 Million USD | 24.64% |
| 2021 Q3 | 127.72 Million USD | -5.8% |
| 2021 FY | 541.53 Million USD | 28.68% |
| 2020 Q1 | 105.68 Million USD | -13.67% |
| 2020 FY | 420.83 Million USD | -0.05% |
| 2020 Q2 | 75.5 Million USD | -28.56% |
| 2020 Q3 | 117.48 Million USD | 55.6% |
| 2020 Q4 | 128.54 Million USD | 9.42% |
| 2019 Q4 | 122.42 Million USD | 16.95% |
| 2019 Q2 | 102.6 Million USD | 12.37% |
| 2019 Q3 | 104.68 Million USD | 2.03% |
| 2019 FY | 421.02 Million USD | 24.83% |
| 2019 Q1 | 91.31 Million USD | -4.0% |
| 2018 Q3 | 83.44 Million USD | -0.78% |
| 2018 Q1 | 74.6 Million USD | -5.65% |
| 2018 FY | 337.27 Million USD | 17.67% |
| 2018 Q4 | 95.11 Million USD | 13.98% |
| 2018 Q2 | 84.1 Million USD | 12.73% |
| 2017 FY | 286.63 Million USD | 3.71% |
| 2017 Q4 | 79.07 Million USD | 17.44% |
| 2017 Q3 | 67.33 Million USD | -5.07% |
| 2017 Q2 | 70.93 Million USD | 2.38% |
| 2017 Q1 | 69.28 Million USD | -4.96% |
| 2016 Q4 | 72.9 Million USD | 6.65% |
| 2016 Q2 | 69.64 Million USD | 6.36% |
| 2016 Q1 | 65.47 Million USD | -5.55% |
| 2016 FY | 276.37 Million USD | 10.99% |
| 2016 Q3 | 68.35 Million USD | -1.85% |
| 2015 Q1 | 58.31 Million USD | -5.63% |
| 2015 Q4 | 69.32 Million USD | 11.42% |
| 2015 FY | 248.99 Million USD | 25.97% |
| 2015 Q3 | 62.21 Million USD | 5.18% |
| 2015 Q2 | 59.14 Million USD | 1.43% |
| 2014 Q4 | 61.79 Million USD | 18.72% |
| 2014 FY | 197.66 Million USD | 131.05% |
| 2014 Q3 | 52.04 Million USD | 10.35% |
| 2014 Q2 | 47.16 Million USD | 28.65% |
| 2014 Q1 | 36.66 Million USD | 9.23% |
| 2013 Q4 | 33.56 Million USD | 44.31% |
| 2013 Q1 | 11.58 Million USD | 10.88% |
| 2013 FY | 85.55 Million USD | 118.89% |
| 2013 Q2 | 17.14 Million USD | 47.93% |
| 2013 Q3 | 23.25 Million USD | 35.69% |
| 2012 Q2 | 12.34 Million USD | 58.18% |
| 2012 Q1 | 7.8 Million USD | 84.36% |
| 2012 Q3 | 8.48 Million USD | -31.25% |
| 2012 Q4 | 10.45 Million USD | 23.14% |
| 2012 FY | 39.08 Million USD | 149.12% |
| 2011 FY | 15.68 Million USD | 7.74% |
| 2011 Q1 | 3.86 Million USD | 76.31% |
| 2011 Q2 | 3.63 Million USD | -5.88% |
| 2011 Q3 | 3.95 Million USD | 8.8% |
| 2011 Q4 | 4.23 Million USD | 7.0% |
| 2010 Q4 | 2.19 Million USD | -51.65% |
| 2010 Q3 | 4.53 Million USD | 48.35% |
| 2010 Q2 | 3.05 Million USD | -36.14% |
| 2010 Q1 | 4.78 Million USD | 11.67% |
| 2010 FY | 14.56 Million USD | -2.96% |
| 2009 Q3 | 3.76 Million USD | 0.0% |
| 2009 Q4 | 4.28 Million USD | 13.94% |
| 2009 FY | 15 Million USD | 7.76% |
| 2008 FY | 13.92 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | -480.207% |
| Theratechnologies Inc. | 81.76 Million USD | -725.52% |
| Safety Shot Inc | 202.67 Thousand USD | -332942.878% |
| Cosmos Health Inc. | 53.37 Million USD | -1164.551% |
| Cronos Group Inc. | 88.84 Million USD | -659.76% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -52.456% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -55.834% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1989.15% |
| ProPhase Labs, Inc. | 44.38 Million USD | -1420.769% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -5200.181% |
| Dynavax Technologies Corporation | 232.28 Million USD | -190.583% |
| Radius Health, Inc. | 2.88 Billion USD | 76.581% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -34900.21% |
| Alvotech | 91.43 Million USD | -638.213% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -2701.577% |
| Alpha Teknova, Inc. | 36.68 Million USD | -1739.979% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -45.353% |
| SCYNEXIS, Inc. | 140.14 Million USD | -381.642% |
| Harrow Health, Inc. | 130.19 Million USD | -418.444% |
| Biofrontera Inc. | 34.07 Million USD | -1881.092% |
| DURECT Corporation | 8.54 Million USD | -7796.327% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -11.104% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -38.652% |
| OptiNose, Inc. | 70.98 Million USD | -850.847% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -10263.275% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1234.397% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1606.537% |
| SIGA Technologies, Inc. | 139.91 Million USD | -382.412% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -426.253% |
| Shineco, Inc. | 9.8 Million USD | -6786.226% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 33.675% |
| Procaps Group S.A. | 409.92 Million USD | -64.661% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -51741.628% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 95.625% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -2701.577% |
| Rockwell Medical, Inc. | 83.61 Million USD | -707.274% |
| Incannex Healthcare Limited | 12 Thousand USD | -5624716.667% |
| Aytu BioPharma, Inc. | 81 Million USD | -733.286% |
| Tilray Brands, Inc. | 788.94 Million USD | 14.445% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -19.093% |
| PetIQ, Inc. | 1.1 Billion USD | 38.748% |
| Silver Spike Investment Corp. | 11.72 Million USD | -5658.15% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 64.232% |
| Journey Medical Corporation | 79.18 Million USD | -752.449% |
| Alimera Sciences, Inc. | 80.75 Million USD | -735.845% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -11492.804% |
| Assertio Holdings, Inc. | 152.06 Million USD | -343.863% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | 39.777% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -62606.695% |
| Procaps Group, S.A. | 409.92 Million USD | -64.661% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -2313.825% |
| Hempacco Co., Inc. | 4.04 Million USD | -16584.097% |
| Talphera, Inc. | 651 Thousand USD | -103583.257% |
| Alvotech | 91.43 Million USD | -638.213% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 47.936% |
| Kamada Ltd. | 144.75 Million USD | -366.278% |
| Indivior PLC | 1.09 Billion USD | 38.245% |
| Currenc Group, Inc. | 53.25 Million USD | -1167.437% |
| Evoke Pharma, Inc. | 5.18 Million USD | -12928.879% |
| Flora Growth Corp. | 76.07 Million USD | -787.3% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -62606.695% |
| Evolus, Inc. | 202.08 Million USD | -234.007% |
| HUTCHMED (China) Limited | 837.99 Million USD | 19.454% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -4.746% |
| Akanda Corp. | 2.16 Million USD | -31148.229% |